Waverley Pharma (TSXV:WAVE) Debt-to-Asset : 2.05 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma Debt-to-Asset?

Waverley Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$1.72 Mil. Waverley Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil. Waverley Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was C$0.84 Mil. Waverley Pharma's debt to asset for the quarter that ended in Mar. 2024 was 2.05.

Waverley Pharma Debt-to-Asset Historical Data

The historical data trend for Waverley Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma Debt-to-Asset Chart

Waverley Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.07

0.26

1.68

Waverley Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.32	0.40	0.56	1.68	2.05

Competitive Comparison of Waverley Pharma's Debt-to-Asset

For the Biotechnology subindustry, Waverley Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Waverley Pharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Waverley Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Waverley Pharma's Debt-to-Asset falls into.

Waverley Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Waverley Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.602	+	0)	/	0.952
	=	1.68

Waverley Pharma's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.715	+	0)	/	0.838
	=	2.05

Waverley Pharma (TSXV:WAVE) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Waverley Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Waverley Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Waverley Pharma (TSXV:WAVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

5GZ:Germany

Address

1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6

Website

https://www.waverleypharma.com

Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.

Executives

Albert David Friesen

10% Security Holder, Director, Senior Officer